Advertisement

Regulatory Aspects of Dose Calculations

  • Michael G. Stabin

Keywords

International Atomic Energy Agency Radiation Protection Nuclear Regulatory Commission Special Nuclear Material Total Effective Dose Equivalent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    International Commission on Radiological Protection. 1990 Recommendations of the International Commission on Radiological Protection. ICRP Publication 60. Pergamon Press, New York, 1991.Google Scholar
  2. 2.
    Taylor L. Organization for Radiation Protection, The Operations of the ICRP and NCRP, 1928-1974. DOE/TIC 10124. U.S. Department of Energy, Washington, DC, 1979.Google Scholar
  3. 3.
    Stabin MG. Radiation Protection and Dosimetry. Springer, New York, 2007.Google Scholar
  4. 4.
    U.S. Food and Drug Administration. Guidance for Industry Developing Medical Imaging Drug and Biological Products, Part 1: Conducting Safety Assessments. U.S. FDA, Washington, DC, 2004.Google Scholar
  5. 5.
    U.S. Food and Drug Administration. Guidance for Industry Developing Medical Imaging Drug and Biological Products Part 3: Design, Analysis, and Interpretation of Clinical Studies. U.S. FDA, Washington, DC, 2004.Google Scholar
  6. 6.
    Radioactive Drug Research Committee (RDRC) Program. US Food and Drug Administration. Available at http://www.fda.gov/cder/regulatory/RDRC/default.htm.Google Scholar
  7. 7.
    Atomic Energy Act, Public Law 83-703, as amended, 42 USC 2011 et seq., 1954.Google Scholar
  8. 8.
    Agreement State Program. US Nuclear Regulatory Commission. Available at http://www.nrc.gov/about-nrc/state-tribal/agreement-states.html.Google Scholar
  9. 9.
    Siegel JA. Tracking the origin of the NRC 30-mCi rule. J Nucl Med 41:10N–16N, 2000.PubMedGoogle Scholar
  10. 10.
    Available at http://www.nrc.gov/reading-rm/doc-collections/cfr/part035/.Google Scholar
  11. 11.
    Rutar FJ, Augustine SC, Colcher D, Siegel JA, Jacobson DA, Tempero MA, Dukat VA, Hohenstein MA, Gobar LS, Vose JM. Outpatient treatment with 131I-anti-B1 antibody: radiation exposure to family members. J Nucl Med 42:907–915, 2001.PubMedGoogle Scholar
  12. 12.
    Marcus CS, Siegel JA. NRC Absorbed dose reconstruction for family member of 131I therapy patient: case study and commentary. J Nucl Med 45:13N–16N, 2004.PubMedGoogle Scholar
  13. 13.
    Siegel JA, Marcus CS, Sparks RB. Calculating the absorbed dose from radioactive patients: the line-source versus point-source model. J Nucl Med 43:1241–1244, 2002.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Michael G. Stabin
    • 1
  1. 1.Department of Radiology/Radiological SciencesVanderbilt UniversityNashvilleUSA

Personalised recommendations